If you are researching non-invasive skin tightening and facial lifting, clinic marketing and manufacturer promotions make an alluring claim for Sofwave: a next-generation "non-surgical mini-facelift" that lifts sagging eyebrows, tightens jowls, smooths submental neck tissue, and reduces cellulite with "over 80% patient improvement" and minimal downtime.
The short clinical answer to whether Sofwave works is yes, but strictly as a subtle, millimeter-scale tissue tightening in cleared adults aged 22 and older—not as an FDA-approved surgical facelift replacement, not as a deep SMAS treatment, and not with an 80% patient satisfaction rate.
Behind the promotional before-and-after photos lies a specific set of 510(k) regulatory clearances, objective 2D imaging measurements, and an important divergence between blinded photograph reviewers and real-world patient questionnaires. Dollar ranges belong on the Sofwave cost page; this page owns whether the 510(k) numbers support a lift claim.
[Sofwave Regulatory and Clinical Summary]
Regulatory Classification: FDA-Cleared Class II Medical Device (510(k) Notification)
Product Code / Regulation: OHV (21 CFR 878.4590) — Focused Aesthetic Ultrasound
Acoustic Frequency: 10 MHz to 12 MHz (High Frequency, Dermal-Specific)
Anatomical Target Depth: 1.0 mm to 2.0 mm (Centered at ~1.5 mm Mid-Dermis)
SMAS Layer Involvement: None (Does NOT reach the 4.5 mm SMAS or platysma)
Pivotal Brow Lift (K211483):0.78 mm Mean Maximal Lift; 79% Masked Photo-ID
Patient Questionnaire: 55% Patient-Rated Improvement & Satisfaction (Eyebrow)
Labeled Population Age: Adults aged 22 and older
Direct Answer: Does Sofwave Actually Work?
For a patient evaluating whether Sofwave's SUPERB (Synchronous Ultrasound Parallel Beam) technology justifies the financial investment:
- What it achieves: Measurable structural compacting of the mid-to-upper reticular dermis, fine line reduction, and modest tissue elevation. In FDA pivotal trials, eyebrow elevation averaged 0.78 mm of maximal lift (0.69 mm average lift), accompanied by a mean reduction of 38 mm² in 2D submental neck surface area.
- What it cannot do: It will not reposition deep fascial structures, excise excess redundant skin folds, debulk submental fat pads, or duplicate the structural results of a surgical deep-plane facelift or neck lift.
- How it works: SUPERB (Synchronous Ultrasound Parallel Beam) is marketed as seven parallel thermal coagulation zones (tissue temperature 60°C to 70°C in the K211483 characteristics table) centered in the mid-dermis at about 1.5 mm. The 510(k) describes an array of piezoelectric plates measuring 7 × 5 mm² each, not a count of seven transducers. Integrated thermoelectric contact cooling (Sofcool) is intended to protect the epidermis.
- The "80% Improved" Nuance: The widely quoted ~80% improvement figure represents blinded, masked photograph reviewers correctly identifying post-treatment photos in clinical trial K211483 (79% brow, 80% neck). On identical subjects, patient self-assessment questionnaires recorded 55% improvement and satisfaction.
- Procedural discomfort: Significant heat and stinging during pulse delivery. In clinical trials, mean pain was scored 6.4 out of 10 on the forehead and 5.3 out of 10 on the neck.
- Cost expectations: Session price varies by area and market; see Sofwave cost rather than treating this page as a second price list.
What Did the FDA Actually Clear (510(k) vs. Facelift PMA)?
Sofwave is frequently marketed as "FDA approved." In US regulatory law, there is a fundamental distinction between 510(k) Premarket Clearance and Premarket Approval (PMA):
[Medical Device Regulatory Pathways]
510(k) Premarket Notification Premarket Approval (PMA)
───────────────────────────── ────────────────────────
• Class II (Moderate Risk) • Class III (High Risk)
• "FDA Cleared" • "FDA Approved"
• Demonstrates Substantial • Independent proof of clinical
Equivalence to Predicates safety and effectiveness
• Example: Sofwave System (OHV) • Example: Breast Implants, PMMA Fillers
In the FDA 510(k) database (openFDA live query 30 August 2026, applicant "Sofwave Medical," total 12 records; matching a 24 August 2026 510(k) dump of 175,559 rows), Sofwave Medical holds clearances under two product codes:
[Sofwave Medical 510(k) Regulatory Timeline]
510(k) # Decision Date Product Code / Name Cleared Indication Scope
──────── ───────────── ─────────────────── ────────────────────────────────────────
K191421 2019-09-09 OHV (Sofacia) Wrinkles and fine lines (dermatological)
K211483 2021-11-15 OHV (SofWave) Lifting the eyebrow; lifting lax submental
and neck tissue (Age ≥ 22)
K223237 2022-12-16 OHV (SofWave) Short-term improvement of cellulite
K230019 2023-03-14 OHV (SofWave) Additional OHV row (not an indication rewrite)
K230820 2023-04-18 OHV (SofWave) Additional OHV row
K231537* 2023-08-28 OHV (SofWave) Database row present; summary PDF unposted
K232455 2023-12-14 OHV (SofWave) Additional OHV row
K233104 2023-12-22 OHV (SofWave) Acne scars; upper-arm skin laxity
K240687 2024-05-30 OHV (SofWave) Later OHV file (K241685 names it as predicate)
K241685 2024-08-07 NGX and OHV SofWave System plus Pure Impact (EMS arms)
K250146 2025-04-18 NGX Pure Impact module update
K251746 2025-07-02 NGX (Pure Impact) Standalone EMS console clearance
*FDA database row exists, but the summary PDF was not posted (FDA HTML 404).
Cleared Indications vs. Off-Label Marketing
- Eyebrow Lift (K211483): Non-invasive dermatological aesthetic treatment to lift the eyebrow in patients aged 22 and older.
- Submental & Neck Lift (K211483): Non-invasive treatment to lift lax submental tissue and lax neck tissue.
- Wrinkles & Fine Lines (K191421): Dermatological treatment for facial lines and rhytids.
- Acne Scars & Upper Arms (K233104): Improving the appearance of acne scars and lax skin on the upper arms.
- Cellulite Appearance (K223237): Cleared for short-term improvement in the appearance of cellulite—not permanent cellulite eradication.
Technical Mechanism: 10 to 12 MHz SUPERB vs. 4.5 mm SMAS Ultherapy
A critical clinical difference between energy-based skin tightening devices is operating frequency and target anatomical depth.
(Correction note: Some older online resources and early web summaries erroneously stated Sofwave operates at 2 MHz. Official 510(k) engineering tables in K191421 and K211483 confirm Sofwave operates at 10 MHz to 12 MHz).
[Acoustic Depth and Target Anatomy]
Depth (mm) Tissue Layer Sofwave SUPERB (10–12 MHz) Ultherapy (4–7 MHz)
────────── ────────────────────── ────────────────────────── ───────────────────
0.0 mm Epidermis (Skin Surface) Protected by contact cooling Bypassed
1.0–2.0 mm Mid-Reticular Dermis PRIMARY THERMAL TARGET Treated (1.5 mm)
3.0 mm Deep Reticular Dermis Unreached Treated (3.0 mm)
4.5 mm SMAS / Platysma Fascia Unreached PRIMARY TARGET
> 5.0 mm Subcutaneous Fat / Bone Completely Protected Risk of Bony Aching
[Ultherapy Focal Dots vs. Sofwave Parallel Cylinders]
Ultherapy (MFU-V): Sofwave (SUPERB):
Individual Micro-Dots Parallel 3D cylinders
┌───────────────────────┐ ┌───────────────────────┐
│ (•) (•) (•) (•)│ 1.5mm │ ═════════════════════ │ 1.5mm
│ (•) (•) (•) (•)│ 3.0mm │ (Uniform Thermal Band)│ (Mid-Dermis)
│ (•) (•) (•) (•)│ 4.5mm │ │
└───────────────────────┘ └───────────────────────┘
1. The SUPERB Energy Pattern
Traditional micro-focused ultrasound (such as Ultherapy) focuses acoustic waves into small, discrete focal points (0.5 to 1.0 mm³ TCPs) at varying depths (1.5 mm, 3.0 mm, and 4.5 mm).
Sofwave SUPERB is marketed as seven synchronous parallel beams creating mid-dermal cylindrical coagulation zones at 1.0 to 2.0 mm (centered at about 1.5 mm). The 510(k) characteristics table lists piezoelectric plates measuring 7 × 5 mm² (a plate size, not a transducer count) and tissue heating of 60°C to 70°C. That is mid-dermal thermal injury plus contact cooling, not a SMAS-depth facelift.
2. Does Sofwave Treat the SMAS?
No. The superficial muscular aponeurotic system (SMAS) and platysma fascia lie at depths of 3.5 mm to 4.5 mm in the lower face and neck. Sofwave's high 10–12 MHz acoustic energy is intentionally absorbed within the first 2 mm of tissue. It creates true dermal compacting and tightening, but it does not anchor or hoist the deep SMAS layer.
For an in-depth comparison of deep SMAS ultrasound versus mid-dermal ultrasound versus radiofrequency, see Ultherapy vs. Sofwave vs. Thermage and our review of Ultherapy clinical efficacy data.
Clinical Trial Data: 0.78 mm Eyebrow Lift vs. 55% Patient Satisfaction
To understand whether Sofwave works, we must analyze the actual clinical trial data submitted to the FDA under pivotal clearances K211483 and K191421.
[Sofwave FDA Pivotal Trial Results (K211483)]
Clinical Endpoint (N=80 Treated) Eyebrow Lift Study Submental / Neck Study
──────────────────────────────── ────────────────── ──────────────────────
Masked Reviewer Photo-ID Rate 79% (53/67 Correct) 80% (60/75 Correct)
Mean Maximal Eyebrow Height (MEH) 0.78 mm Lift N/A
Average Eyebrow Height (AEH) 0.69 mm Lift N/A
Mean 2D Submental Surface Lift N/A 38 mm² Area Reduction
Investigator PGAIS (% Improved) 80% (51/64) 85% (61/72)
Patient Improvement Rating 55% Improved 55% Improved
Patient Satisfaction Rating 55% Satisfied 50% Satisfied
Mean Procedural Pain Score (0–10) 6.4 (Forehead/Brow) 5.3 (Submental/Neck)
[Sofwave Wrinkle Clearance Results (K191421)]
Study Population: 59 Treated / 60 Enrolled (Fitzpatrick Wrinkle Scale)
Masked Photo-ID Success Rate: 78% (45 of 58 Subjects Correctly Identified)
Patient-Reported Outcome: 59% Satisfied | 26% No Change | 15.5% Dissatisfied | 2% Worse
Mean Procedural Pain Score: 7.49 out of 10 (Moderate to High Intra-Op Pain)
Analyzing the Blinded Photo vs. Patient Satisfaction Gap
- The 0.78 mm Measurement: In K211483, blinded 2D digital photographic analysis measured a mean maximal eyebrow elevation of 0.78 millimeters and an average elevation of 0.69 millimeters. That is a real, small 2D photo endpoint. It is not a surgical brow-lift displacement, and it is not a jowl guarantee.
- Why Reviewers Saw 79% but Only 55% of Patients Were Satisfied: Masked reviewers in K211483 correctly ordered pre/post brow photos for 79% (53/67) of treated subjects. The same file's patient questionnaire showed 55% improvement and satisfaction for eyebrow lift. Those are different endpoints, not a fake 80% and a fake 55%. Neither number is a surgical-lift guarantee.
- Acne Scar & Upper Arm Data (K233104): In the upper arm laxity trial (46 enrolled subjects receiving 2 treatments), 93% of treated arms showed measurable improvement in skin firmness at 3 months post-treatment.
Modality Head-to-Head: Sofwave vs. Ultherapy vs. Thermage vs. Morpheus8
Prospective patients seeking non-surgical lifting often struggle to understand how Sofwave compares with other leading capital energy platforms:
[Non-Surgical Energy Platform Comparison Matrix]
Feature Sofwave (SUPERB) Ultherapy (MFU-V) Thermage FLX (RF) Morpheus8 (RFM)
───────────────── ──────────────────── ──────────────────── ─────────────────── ───────────────────
Energy Type Parallel Ultrasound Micro-Focused US Monopolar RF Bipolar RF + Needles
Frequency 10 MHz – 12 MHz 4 MHz – 7 MHz 6.78 MHz 1 MHz
Anatomical Depth 1.5 mm (Mid-Dermis) 1.5 / 3.0 / 4.5 mm Up to 3.0–4.0 mm 0.5 mm to 4.0/8.0 mm
SMAS Targeting No YES (4.5 mm) No Variable
Fat Atrophy Risk Not a lipolysis device Low (if misdirected) Low Moderate (Deep Tips)
Real-Time Imaging No YES (DeepSEE) No No
Epidermal Downtime None (Intact Skin) None (Intact Skin) None (Intact Skin) 1–3 Days Micro-Crusts
Fitzpatrick / PIH Not melanin-targeted Not melanin-targeted Not melanin-targeted More epidermal injury
Primary Indication Dermal Crepiness/Lift Structural Lift (SMAS)Bulk Tissue Tighten Texture + Contouring
What a Session Feels Like, and Why Pain Scores Matter
K191421 and K211483 reported mean intra-procedural pain of 7.49 / 10 (wrinkles) and 6.4 / 10 on the brow zone and 5.3 / 10 on the neck zone. Those are moderate scores from the clearance files, not a "lunchtime with no sensation" procedure.
Clinics typically pair SUPERB pulses with topical anesthetic, coupling gel, and contact cooling. Pulse counts, anesthetic choice, and whether nitrous oxide is offered are clinic protocols, not an FDA-labeled recipe. The 510(k)s do not publish a universal full-face pulse number or a compounded lidocaine/tetracaine formula.
What Is Pure Impact (and Why NGX Is Not Ultrasound Evidence)?
Sofwave later added Pure Impact, a powered muscle stimulator. Live openFDA dates: K241685 (August 7, 2024; product codes NGX and OHV), K250146 (April 18, 2025; NGX), and standalone K251746 (July 2, 2025; NGX).
Patients frequently confuse Pure Impact with Sofwave ultrasound:
[Sofwave Ultrasound vs. Pure Impact EMS]
Attribute Sofwave SUPERB Module Pure Impact Module
───────────────────── ───────────────────────────── ──────────────────────────────
Product Code OHV (21 CFR 878.4590) NGX (21 CFR 890.5850)
Regulatory Device Type Focused Ultrasound System Powered Muscle Stimulator
Target Tissue Mid-Dermis (Collagen/Elastin) Skeletal Muscle Fibers
Mechanism Thermal Coagulation (60–70°C) Electrical Muscle Stimulation (EMS)
Cleared Purpose Lifting Brow/Neck; Wrinkles Muscle Conditioning & Toning
The Regulatory Boundary
- Pure Impact is an Electrical Muscle Stimulator (EMS): It uses multi-directional plyometric electrode pulses to stimulate muscle contraction on the abdomen, buttocks, and limbs.
- Console Sharing vs. Clinical Proof: Clearance K241685 cleared a dual console containing both technologies. However, electrical muscle stimulation under product code NGX is not evidence that ultrasound lifts skin.
- Contraindication Separation: Sofwave's online safety documentation combines warnings for both devices. Contraindications involving transthoracic electrode placement, cardiac pacemakers, and implanted electronic defibrillators apply specifically to Pure Impact electrical currents, not to focused ultrasound energy.
Skin of Color: Mechanism, Not a Measured PIH Rate
Ultrasound is not an optical laser. SUPERB does not use melanin as a chromophore; K191421 and K211483 describe mid-dermal thermal coagulation with thermoelectric epidermal cooling. That mechanism is why clinics often treat Fitzpatrick IV–VI with ultrasound rather than with pigment-seeking lasers.
The lift 510(k)s do not report a PIH incidence such as "<1%," and K191421's "Fitzpatrick" scale is the Wrinkle and Elastosis Scale, not a Fitzpatrick I–VI skin-type table. Do not read color-blind physics as a quantified PIH trial. Ask the treating clinic what skin types they actually enrolled in their own before-and-after set, and whether they have treated similar tones with this handpiece.
Who Should Skip Sofwave? (Non-Candidates and Limitations)
Setting rigorous clinical boundaries prevents procedural dissatisfaction and wasted expenditures:
[Patient Candidacy Decision Matrix]
Ideal Sofwave Candidate Who Should Skip Sofwave
─────────────────────────────────────── ──────────────────────────────────────────
• Age 22+ with mild-to-moderate laxity • Severe, heavy jowling or descended SMAS
• Early brow descent seeking subtle 1 mm lift • Separated platysma neck bands (turkey neck)
• Crepey, thinning mid-dermal texture • Heavy submental fat pads (needs debulking)
• Wanting mid-dermal change without laser PIH • Under age 22 (outside labeled clearance)
• Patients seeking no surgical downtime • Patients expecting a surgical facelift result
1. Severe Jowling and Platysmal Neck Bands
If facial laxity is driven by a descended SMAS layer, deep buccal fat pad descent, or separated platysmal muscle bands in the anterior neck, energy deposited at 1.5 mm in the mid-dermis cannot overcome structural gravitational descent. These patients require a surgical facelift or platysmaplasty. See our guide to treating jowls with and without surgery.
2. Heavy Submental Fat
Sofwave does not cause lipolysis (fat destruction) and does not debulk excess adiposity. A heavy double chin requires cryolipolysis, deoxycholic acid, or submental liposuction before dermal tightening is considered.
3. Patients Expecting Dramatic Centimeter-Scale Changes
If a patient evaluates results by expecting dramatic cheekbone elevation or complete wrinkle eradication, a 0.78 mm brow lift and 55% satisfaction probability will result in disappointment.
Frequently Asked Questions
Does Sofwave really work?
Yes, for mild to moderate skin laxity and fine lines in adults aged 22 and older. In FDA clinical trials (K211483), Sofwave produced an objective 0.78 mm mean maximal lift of the eyebrow and visible firming of submental neck tissue. It does not replace a surgical facelift.
How much lift does Sofwave give?
In 2D photographic imaging trials evaluated by the FDA, the average brow lift was 0.69 mm, with a maximal lift averaging 0.78 mm.
Is Sofwave better than Ultherapy?
Sofwave and Ultherapy serve different anatomical purposes:
- Sofwave (10–12 MHz): Treats at about 1.5 mm mid-dermis; useful for crepiness and fine lines; does not reach SMAS; not a fat-reduction device.
- Ultherapy (4–7 MHz): Can treat 1.5 / 3.0 / 4.5 mm including SMAS-depth targets; different lift claim, different pain pattern. Read the head-to-head on Ultherapy vs. Sofwave vs. Thermage.
Does Sofwave tighten jowls?
Sofwave improves mild skin crepiness along the jawline. However, if jowls are caused by descended fat pads or stretched SMAS fascia, Sofwave's 1.5 mm dermal depth will not lift true structural jowls.
Is Sofwave FDA approved?
Sofwave is FDA cleared as a Class II medical device via the 510(k) premarket notification process under product code OHV (21 CFR 878.4590). It is not a Premarket Approved (PMA) Class III surgical device.
How painful is Sofwave?
Sofwave treatments involve noticeable heat and stinging. In FDA clinical submissions, patients reported mean pain scores of 6.4 out of 10 on the forehead (Zone 1) and 5.3 out of 10 on the neck (Zone 3). Clinics may use topical anesthetic or other comfort measures; those are practice choices, not a labeled formula.
Sources
- FDA CDRH — 510(k) Premarket Notification K211483 Summary (SofWave System Eyebrow and Submental/Neck Lift Clearance, Cleared November 15, 2021): https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211483.pdf
- FDA CDRH — 510(k) Premarket Notification K191421 Summary (Sofacia System Wrinkle Clearance, Cleared September 9, 2019): https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191421.pdf
- FDA CDRH — 510(k) Premarket Notification K233104 Summary (SofWave System Acne Scars and Upper Arm Laxity, Cleared December 22, 2023): https://www.accessdata.fda.gov/cdrh_docs/pdf23/K233104.pdf
- FDA CDRH — 510(k) Premarket Notification K223237 Summary (SofWave System Short-Term Cellulite Appearance, Cleared December 16, 2022): https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223237.pdf
- FDA CDRH — 510(k) Premarket Notification K241685 Summary (SofWave System with Pure Impact Dual Clearance, Cleared August 7, 2024): https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241685.pdf
- FDA CDRH — 510(k) Premarket Notification K251746 Summary (Pure Impact Standalone Powered Muscle Stimulator, Cleared July 2, 2025): https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251746.pdf
- Electronic Code of Federal Regulations (eCFR) — 21 CFR 878.4590 Focused Ultrasound Stimulator System for Aesthetic Use: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878/subpart-E/section-878.4590
- FDA CDRH — Product Classification Database Record for OHV (Focused Aesthetic Ultrasound): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=OHV
- FDA CDRH — Product Classification Database Record for NGX (Powered Muscle Stimulator, 21 CFR 890.5850): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID=NGX
- openFDA — 510(k) Device Database API (Live Registry Search for Applicant "Sofwave Medical"): https://open.fda.gov/apis/device/510k/
- American Society for Dermatologic Surgery (ASDS) — Non-Surgical Skin Tightening Technologies: https://www.asds.net/skin-experts/skin-treatments/skin-tightening
- American Society of Plastic Surgeons (ASPS) — Ultrasound Skin Rejuvenation Guide: https://www.plasticsurgery.org/cosmetic-procedures/non-surgical-skin-tightening
